evo真人视讯

A delegation led by Chief President Zhang Fei from the Shenzhen Nanshan Medical Group Headquarters visited Shenzhen Cell Valley to explore new opportunities in the development of cell therapy industr

Date:03-12  Hits:  Belong to:Corporate News

On March 11, 2026, a delegation from the Shenzhen Nanshan Medical Group Headquarters, including Chief President Zhang Fei, Deputy Chief Presidents Mo Beirong and Huang Cao,  Deputy Director Zhu Ronghui from the Community Management Department, Deputy Director Xu Quancheng from the Quality Department, and Director Li Chengliang, visited Shenzhen Cell Valley for collaboration discussions. The exchange focused on topics such as clinical translation of cell and gene therapy (CGT) technologies, collaborative innovation among industry, academia, research, and healthcare, and industrial cooperation under policy compliance. Shenzhen Cell Valley's Chairman and General Manager, Professor Shi Yuan, Administrative Director Wei Zheng, and Chairman's Assistant Fu Yuchen, 、 warmly received the delegation.

 

Chairman's Assistant Fu Yuchen accompanied the delegation on a tour of Shenzhen Cell Valley's smart exhibition hall, R&D laboratories, and GMP production facilities. They observed the standardized R&D and production environment, the full-process quality control system, and gained an initial understanding of the core technological R&D and industrial operation achievements in cell therapy. 

 

During the symposium, Professor Shi Yuan, Chairman of Shenzhen Cell Valley, provided a detailed introduction to the company's development journey, core technology pipeline, R&D strategic layout, latest progress in Shenzhen-Hong Kong collaboration, and innovative explorations in the field of cell therapy. He emphasized the development philosophy of " prioritizing clinical needs to bring cutting-edge technologies to benefit the public ", development opportunities under new policies, models for hospital-enterprise collaboration, and innovative pathways for Shenzhen-Hong Kong medical integration. He explicitly stated that Shenzhen Cell Valley is willing to collaborate with the Nanshan Medical Group Headquarters, leveraging their respective strengths to tackle technical challenges in cell therapy, accelerate the translation of research outcomes, and contribute to elevating regional healthcare standards.

 

Chief President Zhang Fei noted in his remarks that as a core entity for regional healthcare services, the Nanshan Medical Group has always prioritized introducing advanced medical technologies, focusing on chronic disease management and intervention, and enhancing clinical service capabilities. He highlighted the strong complementarity between Shenzhen Cell Valley's technological strengths and industrial capabilities in CGT and the Nanshan Medical Group's clinical resources and service network. He expressed hope that this exchange would serve as a starting point for establishing a regular collaboration mechanism, jointly exploring the full-chain collaborative innovation model of " basic research - technology translation - clinical application " to bring more cutting-edge biotechnological benefits to local residents.

 

This visit and exchange not only enhanced mutual understanding between both parties but also laid a solid foundation for in-depth collaboration in the future. Shenzhen Cell Valley will continue to leverage its technological and platform advantages, deepen its expertise in the field of cell and gene therapy, drive breakthroughs and upgrades in the cell industry, and contribute to the innovative development of the biopharmaceutical industry.



 Headquarters of Shenzhen Nanshan Medical Group

 图片.png图片.pngShenzhen Nanshan Medical Group is a public institution under the leadership of the Health Work Committee of Shenzhen Nanshan District Committee and established by the Health Bureau of Shenzhen Nanshan District. The medical group operates under a 1+C+N model. "1" refers to the Headquarters of Shenzhen Nanshan Medical Group (including 81 subordinate community health service institutions, hereafter the same), "C" represents member units, which are district-owned public medical and health institutions, including Huazhong University of Science and Technology Union Shenzhen Hospital, Shekou People's Hospital, Southern University of Science and Technology Hospital, Nanshan District Maternity and Child Healthcare Hospital, Nanshan District Center for Disease Control and Prevention, and Nanshan District Chronic Disease Prevention and Treatment Hospital; "N" denotes other medical and health institutions in the district. The medical group aims to adopt a problem-oriented approach, with the direction of "building high ground and strengthening grassroots," by guiding the al of medical resources to the community level to enhance the service capacity of community health centers, promote tiered diagnosis and treatment, and facilitate two-way referrals. Through the implementation of integrated and refined management, it seeks to improve the service quality and standardization of community health centers. By consolidating medical and health resources, it aims to maximize the sharing and utilization efficiency of these resources. Through the establishment of a modern hospital management system, it ensures the public welfare nature of public hospitals and fosters their development. With 3-5 years of relentless effort, the group aspires to build a high-quality grassroots medical and health professional team, create a standardized Nanshan community health service quality brand, and establish a first-class integrated high-quality medical service system.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Bottom Navigation
Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software